Our lab conducts translational oncology research through early stage clinical studies inspired by nanotechnologies, systems biology, and biomarker driven therapies. We focus on solid tumors with an emphasis on highly lethal subtypes such as ovarian cancers. We subscribe to both “high-tech” and “low-tech” theranostic approaches that leverage innovative advances within CSB. To date, these efforts have generated traction both domestically and abroad. We are currently establishing a comprehensive multi-departmental program to prospectively profile gynecologic cancers including multi-omics (sequencing, proteomics, liquid biopsies), pathology (digital and multiplexed profiling), imaging and clinical phenotypes. We seek to ultimately advance cancer theranostics by better understanding the spatiotemporal evolution of cancers and uncovering novel treatment response readouts using integrated machine learning and statistical inferences. Our work has been externally funded by the National Cancer Institute, Robert Wood Johnson Foundation, V Foundation for Cancer Research, Ovarian Cancer Research Fund, and the Department of Defense.
Chin LK*, Son T*, Hong JS, Liu AQ, Skog J, Castro CM, Weissleder R, Lee H*, Im H* Plasmonic Sensors for Extracellular Vesicle Analysis: From Scientific Development to Translational Research. ACS Nano. 2020;14(11):14528-14548 - PMID: 33119256 - DOI: 10.1021/acsnano.0c07581
Yang KS, Lin HY, Curley C, Welch MW, Wolpin BM, Lee H, Weissleder R, Im H*, Castro CM* Bead-Based Extracellular Vesicle Analysis Using Flow Cytometry. Adv Biosyst. 2020;4(12):e2000203 - PMID: 33103361 - PMCID: PMC7718389 - DOI: 10.1002/adbi.202000203
Min J*, Chin LK*, Oh J, Landeros C, Vinegoni C, Lee J, Lee SJ, Park JY, Liu AQ, Castro CM, Lee H, Im H, Weissleder R CytoPAN—Portable cellular analyses for rapid point-of-care cancer diagnosis. Sci Transl Med. 2020;12:eaaz9746 - PMID: 32759277 - DOI: 10.1126/scitranslmed.aaz9746
O'Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, Martin LP, Mantia-Smaldone GM, Martin AG, Bratos R, Penson RT, Malek K, Moore KN Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2020;157(2):379-385 - PMID: 32081463 - DOI: 10.1016/j.ygyno.2020.01.037
Liu JF, Herold C, Gray KP, Penson RT, Horowitz N, Konstantinopoulos PA, Castro CM, Hill SJ, Curtis J, Luo W, Matulonis UA, Cannistra SA, Dizon DS Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019;:ePub - PMID: 31600397 - PMCID: PMC6802049 - DOI: 10.1001/jamaoncol.2019.3343
- More publications ...